Nanyang Biologics Featured in Equinix Global Case Study on AI-Powered Drug Discovery

We’re honored to announce that Nanyang Biologics (NYB) has been featured in a newly released global case study by Equinix, spotlighting how our proprietary AI-powered DTIGN platform is transforming the future of drug discovery and supported by world-class, scalable infrastructure.

‍

In the video feature, our Chief Technology Officer, Giang Nguyen, shares how NYB combines AI and biological data to predict drug-target interactions with greater accuracy and efficiency. The DTIGN engine enables high-throughput screening of billions of molecules, helping to identify promising therapeutic candidates across oncology, metabolic disease, and neuroscience.

‍

‍

DTIGN: Scalable AI Infrastructure Driving Global Drug Discovery

At the core of Nanyang Biologics’ innovation is DTIGN (Drug-Target Interaction Graph Neural Network) - a proprietary AI engine designed to streamline the discovery and optimization of bioactive compounds. Capable of screening over 2 billion molecules, DTIGN delivers fast, actionable insights for drug development in oncology, metabolic disorders, and neuroscience.

‍

Unlike traditional models that rely solely on structure, DTIGN incorporates real-world outcomes such as potency, efficacy, and toxicity. This hybrid approach improves both hit quality and translational relevance, with 27% higher predictive accuracy and 64x greater screening efficiency than conventional methods.

‍

To support this scale, NYB leverages an enterprise-grade infrastructure built with Equinix, HPE, and NVIDIA, featuring:

• AI-optimized GPU clusters
• Secure private cloud environments
• Energy-efficient cooling systems
• Low-latency global connectivity

‍

This robust setup allows DTIGN to run faster, scale efficiently, and reduce R&D costs by up to 90%, while remaining flexible for growing compound libraries and complex pipelines.

‍

“We aim to be the platform of choice for people looking to discover compounds for drugs and other uses. Scanning natural compound data requires powerful GPUs that consume a lot of energy. That’s why we want to collaborate with organizations like HPE, NVIDIA, and Equinix, who have extensive experience in developing and running data centers, scaling GPUs, and managing IT operations,” - Giang Nguyen, CTO, Nanyang Biologics.

‍

Based in Singapore and Vietnam, Nanyang Biologics demonstrates how regionally driven innovation, powered by world-class infrastructure, can contribute meaningfully to global pharmaceutical advancement.

‍

📽️ Watch the full video: https://surli.cc/zttaaq
📘 Read the full case study: https://surl.li/hbjaak

‍